埃克替尼与吉非替尼治疗老年非小细胞肺癌安全性及生存质量的对比研究  

Contrastive study on security and quality of life of elderly non- small cell lung cancer treated by Icotinib and Gefitinib

作　　者：史英[1] 柳志宝[1] 刘纪红[1] 郭廷廷[1] 

机构地区：[1]河北省沧州市中心医院肿瘤内科,河北沧州061001

出　　处：《临床和实验医学杂志》2016年第23期2316-2319,共4页Journal of Clinical and Experimental Medicine

基　　金：沧州市科技计划项目(编号:131302114)

摘　　要：目的对比观察埃克替尼与吉非替尼治疗老年非小细胞肺癌(NSCLC)的临床安全性和对生存质量的影响。方法将150例老年III期或IV期NSCLC患者随机分为埃克替尼组80例和吉非替尼组70例,分别采取相应药物治疗,当患者发展至进展期或无法耐受时停药,观察两组不良反应情况,采用肺癌患者生存质量量表(QLICP-LU)评定患者生存质量,随访2年后评估两组生存情况。结果两组主要不良反应为皮疹、腹泻、恶心、呕吐及肝功能异常,差异无统计学意义(P>0.05);治疗后埃克替尼组QLICP-LU生存质量评分为(171.38±12.81)分,显著高于吉非替尼组的(166.25±11.45)分(P=0.0111),其中躯体活动、社会功能、共性症状及不良反应模块评分均高于吉非替尼组(P<0.05)。埃克替尼组平均无进展生存期高于吉非替尼组,但Kaplan-Meier生存曲线未见明显统计学差异(P=0.168)。结论埃克替尼用于一线治疗老年NSCLC较吉非替尼有更好的安全性和耐受性,提高患者生存质量、延长生存期。Objective To observe the clinical security and quality of life elderly patients with non- small cell lung cancer（ NSCLC） treated by Icotinib and Gefitinib. Methods One hundred and fifty elderly patients with stage III or IV NSCLC were randomly divided into the Icotinib group（ 80 cases） and the Gefitinib group（ 70 cases）. The medication stopped when patients developed to PD or cannot tolerate. The adverse reactions and progression free survival（ following- up for 2 years） were compared between two groups,and quality of life in patients with lung cancer volume table（ QLICP- LU） was used to evaluate quality of life. Results The adverse reaction includes rash,diarrhea,nausea,vomiting and abnormal liver function,there was no significant difference in two groups（ P〉0. 05）. After treatment,the QLICP- LU scores was higher（ 171. 38 ± 12. 81） in Icotinib group than that in Gefitinib group（ 166. 25 ± 11. 45 scores）,with significant difference（ P = 0. 0111）. There were significant differences of physical function,social function,common symptoms and side effects in tow groups（ P〈0. 05）. In addition,the mean PFS of Icotinib group was longer than that of the Gefitinib group,but the Kaplan- Meier survival curve has no obviously different（ P〉0. 05）. Conclusion Icotinib appears to be high safety and good tolerance in elderly patients with NSCLC compare with Gefitinib. And it can improve patients＇ quality of life and prolong overall survival time.

关 键 词：非小细胞肺癌 埃克替尼 吉非替尼 安全性 生存质量 

分 类 号：R734.2[医药卫生—肿瘤]